Keros Therapeutics will use the proceeds from the Partners Healthcare and Medison Pharma-backed round to push its rare muscle disease drugs into clinical trials.

Keros Therapeutics, a US-based developer of treatments for rare muscle diseases, has collected $23m in a series B round that included pharmaceutical marketing firm Medison Pharma and care provider Partners Healthcare. Arkin Bio Ventures, part of healthcare investment holding company Arkin Holdings, and Global Health Sciences Fund, a venture capital fund set up by Quark…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.